meyer wrote:
“Hiding more evidence, more censorship.....
https://twitter.com/RWMaloneMD/status/1449142757335863297/photo/1
“
At the bottom of the screengrab is the authors list:
Jessica Rose & Peter McCullough
From the twtt:
Robert W Malone, MD
@RWMaloneMD
More Censorship/Cancel Culture. The authors were not notified of this “Temporary Removal” action. I have never seen anything like this, ever, in my entire scientific career.
I did a search on clinicaltrials.gov for it. Not found, granted their search engine leaves a lot to be desired.
-SB
Gone from here
And here (this is the Current Cardiology one Dr Malone mentioned in his twtt); it says that it will be updated then reuploaded:
But it’s still here:
https://pubmed.ncbi.nlm.nih.gov/34601006/
Archiving for comparison when the edited one gets put up:
Skip to main page content
NIH NLM Logo Log in
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced
Review
A Report on Myocarditis Adverse Events in the U.S. Vaccine Adverse Events Reporting System (VAERS) in Association with COVID-19 Injectable Biological Products
Jessica Rose et al. Curr Probl Cardiol. 2021.
Free PMC article
Hide details
Curr Probl Cardiol
. 2021 Sep 30;101011.
doi: 10.1016/j.cpcardiol.2021.101011. Online ahead of print.
Authors
Jessica Rose 1 , Peter A McCullough 2
Affiliations
1 Institute of Pure and Applied Knowledge, Public Health Policy Initiative (PHPI), Texas A & M College of Medicine, Baylor Dallas Campus, Dallas TX USA. Electronic address: jessicarose1974@protonmail.com.
2 Institute of Pure and Applied Knowledge, Public Health Policy Initiative (PHPI), Texas A & M College of Medicine, Baylor Dallas Campus, Dallas TX USA.
PMID: 34601006
PMCID: PMC8483988
DOI: 10.1016/j.cpcardiol.2021.101011
Full text links
Cite
Abstract
Following the global rollout and administration of the Pfizer Inc./BioNTech BNT162b2 and Moderna mRNA-1273 vaccines on December 17, 2020, in the United States, and of the Janssen Ad26.COV2.S product on April 1st, 2021, in an unprecedented manner, hundreds of thousands of individuals have reported adverse events (AEs) using the Vaccine Adverse Events Reports System (VAERS). We used VAERS data to examine cardiac AEs, primarily myocarditis, reported following injection of the first or second dose of the COVID-19 injectable products. Myocarditis rates reported in VAERS were significantly higher in youths between the ages of 13 to 23 (p<0.0001) with ∼80% occurring in males. Within 8 weeks of the public offering of COVID-19 products to the 12-15-year-old age group, we found 19 times the expected number of myocarditis cases in the vaccination volunteers over background myocarditis rates for this age group. In addition, a 5-fold increase in myocarditis rate was observed subsequent to dose 2 as opposed to dose 1 in 15-year-old males. A total of 67% of all cases occurred with BNT162b2. Of the total myocarditis AE reports, 6 individuals died (1.1%) and of these, 2 were under 20 years of age - 1 was 13. These findings suggest a markedly higher risk for myocarditis subsequent to COVID-19 injectable product use than for other known vaccines, and this is well above known background rates for myocarditis. COVID-19 injectable products are novel and have a genetic, pathogenic mechanism of action causing uncontrolled expression of SARS-CoV-2 spike protein within human cells. When you combine this fact with the temporal relationship of AE occurrence and reporting, biological plausibility of cause and effect, and the fact that these data are internally and externally consistent with emerging sources of clinical data, it supports a conclusion that the COVID-19 biological products are deterministic for the myocarditis cases observed after injection.
Keywords: COVID-19; COVID-19-Injection-Related Myocarditis (CIRM); SARS-CoV-2; VAERS; adverse events (AEs); myocarditis.
Copyright © 2021. Published by Elsevier Inc.
Conflict of interest statement
Declaration of Competing Interest Nothing to disclose. Author had access to data and wrote the manuscript.
Publication types
Review
Related information
MedGen
LinkOut - more resources
Full Text Sources
ClinicalKey
Elsevier Science
Europe PubMed Central
PubMed Central
NCBI Literature Resources
MeSH PMC Bookshelf Disclaimer
FOLLOW NCBI
Connect with NLM
National Library of Medicine
8600 Rockville Pike
Bethesda, MD 20894
Web Policies
FOIA
Help
Accessibility
Careers
NLM
NIH
HHS
USA.gov